Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Caliber Imaging & Diagnostics's Days Sales Outstanding or its related term are showing as below:
LCDX's Days Sales Outstanding is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 65.03 * Ranked among companies with meaningful Days Sales Outstanding only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caliber Imaging & Diagnostics Days Sales Outstanding Chart
LCDX vs VICA, CRVW, RSLS: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Caliber Imaging & Diagnostics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caliber Imaging & Diagnostics Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Caliber Imaging & Diagnostics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Caliber Imaging & Diagnostics's Days Sales Outstanding falls into.
Caliber Imaging & Diagnostics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caliber Imaging & Diagnostics (LCDX) has a Days Sales Outstanding of 47.38 as of Mar. 2014. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Caliber Imaging & Diagnostics and its competitors.
Is Caliber Imaging & Diagnostics' Days Sales Outstanding too high?
Caliber Imaging & Diagnostics' current Days Sales Outstanding is 47.38. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.03. Caliber Imaging & Diagnostics' value of 47.38 is 27.1% below this industry median.
How does Caliber Imaging & Diagnostics' Days Sales Outstanding compare to VICA and CRVW?
Caliber Imaging & Diagnostics' Days Sales Outstanding of 47.38 can be compared against companies in the Medical Devices & Instruments industry. The industry median Days Sales Outstanding is 65.03. Caliber Imaging & Diagnostics' value of 47.38 is 27.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.03, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caliber Imaging & Diagnostics's current Days Sales Outstanding of 47.38 is 27.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Caliber Imaging & Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caliber Imaging & Diagnostics's current Days Sales Outstanding is 47.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliber Imaging & Diagnostics stock overvalued right now?
Caliber Imaging & Diagnostics (LCDX) has a current Days Sales Outstanding of 47.38. The current Days Sales Outstanding is 47.38 and 27.1% below the Medical Devices & Instruments industry median of 65.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Caliber Imaging & Diagnostics (LCDX), the current Days Sales Outstanding is 47.38 as of Mar. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caliber Imaging & Diagnostics Inc is a medical device company engaged in developing, manufacturing, marketing & selling point-of-care cellular imaging systems to diagnose skin cancer. It offers clinical imaging and research imaging solutions that shows tissue at the cellular level. Its products portfolio includes; VivaScope; VivaScope 3000, 1500 & 2500; and VivaNet and VivaScan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LCDX has been successfully added to your 
